Target type: cellularcomponent
A pre-organized unit composed either of adhesion molecules (mainly integrins and members of the Ig superfamily), signaling receptors and/or enzyme-enriched plasma membrane domains that compartmentalizes cellular processes. Tetraspanin-enriched microdomains might be specially suited for the regulation of avidity of adhesion receptors and the compartmentalization of enzymatic activities. [GOC:ans, PMID:19709882, PMID:21930792]
Tetraspanin-enriched microdomains (TEMs), also known as tetraspanin web, are specialized plasma membrane microdomains that are enriched in tetraspanin proteins. These domains are characterized by their unique protein composition, which includes a variety of transmembrane proteins, including tetraspanins, integrins, and growth factor receptors, as well as signaling molecules, cytoskeletal proteins, and lipid raft components. TEMs play a critical role in a wide range of cellular processes, including cell adhesion, migration, proliferation, and signal transduction. They are involved in the regulation of various cellular events, such as cell-cell interactions, cell-matrix interactions, and immune responses. The molecular basis for the formation and function of TEMs is still being investigated, but it is believed that tetraspanins act as scaffold proteins, bringing together different proteins and lipids to form these specialized microdomains. TEMs have been implicated in various pathological processes, including cancer, inflammation, and infectious diseases. Further research on TEMs is crucial for understanding their role in health and disease and for developing new therapeutic strategies.'
"
Protein | Definition | Taxonomy |
---|---|---|
Platelet glycoprotein VI | A platelet glycoprotein VI that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HCN6] | Homo sapiens (human) |
Disintegrin and metalloproteinase domain-containing protein 10 | A disintegrin and metalloproteinase domain-containing protein 10 that is encoded in the genome of human. [PRO:WCB, UniProtKB:O14672] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gamma-aminobutyric acid | gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system. | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
biphenyl-2-carboxylic acid | biphenyl-2-carboxylic acid: structure in first source | ||
honokiol | biphenyls | ||
ilomastat | CS 610: matrix metalloproteinase inhibitor; structure in first source ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid | anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent |
olmesartan | olmesartan: an active metabolite of CS 866 | biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent |
cinanserin | cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication. Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity. | aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound | anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
exp-3179 | |||
glaucocalyxin a | glaucocalyxin A: chemical constituent of Rabdosia japonica var. glaucocalyx | ||
bms-566394 | BMS-566394: structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
pci 32765 | ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. ibrutinib: a Btk protein inhibitor | acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide | antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
acp-196 | acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity | aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone | antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |